Current Study: For people who are currently taking Raptiva (efalizumab) for the treatment of psoriasis
People who are currently using Raptiva or other biologics, for treatment of chronic moderate to severe plaque psoriasis may be eligible to participate in a 5 year observational study looking at the long term safety of Raptiva.
Participation in this research study may include the following at no cost:
- Study visits to the University of Iowa Department of Dermatology clinic and study phone calls every six months for 5 years
- Study-related laboratory tests and examinations
Compensation is provided. |
For more information or to consider participation please contact:
Clinical Research Coordinator at (319) 353-6439

|